Unity Biotechnology (NASDAQ:UBX) Stock Rating Upgraded by We

Wedbush upgraded shares of Unity Biotechnology (NASDAQ:UBX – Free Report) from a neutral rating to an outperform rating in a research note released on Thursday morning, Marketbeat Ratings reports. The firm currently has $4.00 target price on the stock. Separately, HC Wainwright reaffirmed a buy rating and issued a $10.00 price target on shares of […]

Related Keywords

, Acadian Asset Management , Geode Capital Management , Vanguard Group Inc , Unity Biotechnology Inc , Nasdaq , Unity Biotechnology Company Profile , Renaissance Technologies , Unity Biotechnology , Free Report , Marketbeat Ratings , Biotechnology Stock Down , Asset Management , Street Corp , Capital Management , Get Free Report , Unity Biotechnology Daily , Nasdaq Ubx , Subx , Medical , Upgrade , Wedbush ,